The stock price of Compass Pathways Plc ADR (NASDAQ: CMPS) has plunged by -4.51 when compared to previous closing price of 4.66, but the company has seen a -9.00% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-14 that LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024.
Is It Worth Investing in Compass Pathways Plc ADR (NASDAQ: CMPS) Right Now?
The 36-month beta value for CMPS is at 2.28. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CMPS is 62.67M, and currently, shorts hold a 8.69% of that float. The average trading volume for CMPS on November 22, 2024 was 850.56K shares.
CMPS’s Market Performance
CMPS stock saw a decrease of -9.00% in the past week, with a monthly decline of -30.90% and a quarterly a decrease of -38.11%. The volatility ratio for the week is 10.65%, and the volatility levels for the last 30 days are 8.70% for Compass Pathways Plc ADR (CMPS). The simple moving average for the past 20 days is -13.63% for CMPS’s stock, with a -41.59% simple moving average for the past 200 days.
Analysts’ Opinion of CMPS
Many brokerage firms have already submitted their reports for CMPS stocks, with RBC Capital Mkts repeating the rating for CMPS by listing it as a “Outperform.” The predicted price for CMPS in the upcoming period, according to RBC Capital Mkts is $23 based on the research report published on July 23, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CMPS reach a price target of $30. The rating they have provided for CMPS stocks is “Overweight” according to the report published on April 01st, 2024.
Deutsche Bank gave a rating of “Buy” to CMPS, setting the target price at $16 in the report published on December 12th of the previous year.
CMPS Trading at -25.32% from the 50-Day Moving Average
After a stumble in the market that brought CMPS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.10% of loss for the given period.
Volatility was left at 8.70%, however, over the last 30 days, the volatility rate increased by 10.65%, as shares sank -30.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.37% lower at present.
During the last 5 trading sessions, CMPS fell by -9.00%, which changed the moving average for the period of 200-days by -58.10% in comparison to the 20-day moving average, which settled at $5.15. In addition, Compass Pathways Plc ADR saw -49.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMPS starting from ATAI Life Sciences N.V., who sale 2,660,000 shares at the price of $6.05 back on Sep 26 ’24. After this action, ATAI Life Sciences N.V. now owns 6,905,774 shares of Compass Pathways Plc ADR, valued at $16,093,000 using the latest closing price.
Malievskaia Ekaterina, the 10% Owner of Compass Pathways Plc ADR, sale 8,900 shares at $7.91 during a trade that took place back on May 21 ’24, which means that Malievskaia Ekaterina is holding 3,931,687 shares at $70,379 based on the most recent closing price.
Stock Fundamentals for CMPS
Current profitability levels for the company are sitting at:
- -45.76 for the present operating margin
- 0.47 for the gross margin
The net margin for Compass Pathways Plc ADR stands at -39.27. The total capital return value is set at -0.76. Equity return is now at value -64.99, with -53.09 for asset returns.
Based on Compass Pathways Plc ADR (CMPS), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -3.28. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -37.61.
Currently, EBITDA for the company is -123.8 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 35.32. The receivables turnover for the company is 0.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.91.
Conclusion
In conclusion, Compass Pathways Plc ADR (CMPS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
